201 related articles for article (PubMed ID: 30932730)
1. A physician's guide to the 2-dose schedule of MenB-FHbp vaccine.
McDaniel A; Dempsey A; Srivastava A
Hum Vaccin Immunother; 2019; 15(11):2729-2737. PubMed ID: 30932730
[TBL] [Abstract][Full Text] [Related]
2. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp.
Burman C; Alderfer J; Snow VT
J Clin Pharm Ther; 2020 Apr; 45(2):270-281. PubMed ID: 31820483
[TBL] [Abstract][Full Text] [Related]
3. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
Vesikari T; Østergaard L; Beeslaar J; Absalon J; Eiden JJ; Jansen KU; Jones TR; Harris SL; Maansson R; Munson S; O'Neill RE; York LJ; Perez JL
Vaccine; 2019 Mar; 37(12):1710-1719. PubMed ID: 30770221
[TBL] [Abstract][Full Text] [Related]
4. Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months.
Østergaard L; Vesikari T; Senders SD; Flodmark CE; Kosina P; Jiang HQ; Maguire JD; Absalon J; Jansen KU; Harris SL; Maansson R; Balmer P; Beeslaar J; Perez JL
Vaccine; 2021 Jul; 39(32):4545-4554. PubMed ID: 34215452
[TBL] [Abstract][Full Text] [Related]
5. Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine - Advisory Committee on Immunization Practices, 2016.
Patton ME; Stephens D; Moore K; MacNeil JR
MMWR Morb Mortal Wkly Rep; 2017 May; 66(19):509-513. PubMed ID: 28520709
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1-9 years: two phase 2 randomised, controlled, observer-blinded studies.
Marshall HS; Vesikari T; Richmond PC; Wysocki J; Szenborn L; Beeslaar J; Maguire JD; Balmer P; O'Neill R; Anderson AS; Prégaldien JL; Maansson R; Jiang HQ; Perez JL
Lancet Infect Dis; 2023 Jan; 23(1):103-116. PubMed ID: 36087588
[TBL] [Abstract][Full Text] [Related]
7. Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults.
Beeslaar J; Absalon J; Balmer P; Srivastava A; Maansson R; York LJ; Perez JL
Vaccine; 2018 Jun; 36(28):4004-4013. PubMed ID: 29861182
[TBL] [Abstract][Full Text] [Related]
8. MenB-FHbp Meningococcal Group B Vaccine (Trumenba
Shirley M; Taha MK
Drugs; 2018 Feb; 78(2):257-268. PubMed ID: 29380290
[TBL] [Abstract][Full Text] [Related]
9. A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults.
Drazan D; Czajka H; Maguire JD; Pregaldien JL; Maansson R; O'Neill R; Anderson AS; Balmer P; Beeslaar J; Perez JL
Vaccine; 2022 Jan; 40(2):351-358. PubMed ID: 34961633
[TBL] [Abstract][Full Text] [Related]
10. Meningococcal-group B (MenB) vaccine series completion and adherence to dosing schedule in the United States: A retrospective analysis by vaccine and payer type.
Packnett E; Irwin DE; Novy P; Watson PS; Whelan J; Moore-Schiltz L; Lucci M; Hogea C
Vaccine; 2019 Sep; 37(39):5899-5908. PubMed ID: 31443990
[TBL] [Abstract][Full Text] [Related]
11. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
[TBL] [Abstract][Full Text] [Related]
12. Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015.
Folaranmi T; Rubin L; Martin SW; Patel M; MacNeil JR;
MMWR Morb Mortal Wkly Rep; 2015 Jun; 64(22):608-12. PubMed ID: 26068564
[TBL] [Abstract][Full Text] [Related]
13. Genetic Diversity of Meningococcal Serogroup B Vaccine Antigens among Carriage Isolates Collected from Students at Three Universities in the United States, 2015-2016.
Marjuki H; Chang HY; Topaz N; Whaley MJ; Vuong J; Chen A; Jenkins LT; Hu F; Schmink S; Retchless AC; Thomas JD; Acosta AM; McNamara LA; Soeters HM; Mbaeyi S; Wang X
mBio; 2021 May; 12(3):. PubMed ID: 34006659
[TBL] [Abstract][Full Text] [Related]
14. Randomized Trial of 2 Schedules of Meningococcal B Vaccine in Adolescents and Young Adults, Canada
Langley JM; Gantt S; Quach C; Bettinger JA; Halperin SA; Mutch J; McNeil SA; Ward BJ; MacKinnon-Cameron D; Ye L; Marty K; Scheifele D; Brown E; Alcantara J;
Emerg Infect Dis; 2020 Mar; 26(3):454-462. PubMed ID: 32091358
[TBL] [Abstract][Full Text] [Related]
15. Meningococcal Carriage Evaluation in Response to a Serogroup B Meningococcal Disease Outbreak and Mass Vaccination Campaign at a College-Rhode Island, 2015-2016.
Soeters HM; Whaley M; Alexander-Scott N; Kanadanian KV; MacNeil JR; Martin SW; McNamara LA; Sicard K; Vanner C; Vuong J; Wang X; Bandy U; Patel M;
Clin Infect Dis; 2017 Apr; 64(8):1115-1122. PubMed ID: 28158417
[TBL] [Abstract][Full Text] [Related]
16. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine.
Perez JL; Absalon J; Beeslaar J; Balmer P; Jansen KU; Jones TR; Harris S; York LJ; Jiang Q; Radley D; Anderson AS; Crowther G; Eiden JJ
Expert Rev Vaccines; 2018 Jun; 17(6):461-477. PubMed ID: 29883226
[TBL] [Abstract][Full Text] [Related]
17. Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults.
Martinón-Torres F; Nolan T; Toneatto D; Banzhoff A
Hum Vaccin Immunother; 2019; 15(12):2940-2951. PubMed ID: 31246520
[TBL] [Abstract][Full Text] [Related]
18. Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults.
Presa J; Burman C; Tort MJ; Cane A; Bocchini JA
Hum Vaccin Immunother; 2023 Dec; 19(1):2212570. PubMed ID: 37257838
[TBL] [Abstract][Full Text] [Related]
19. Modeling persistence of hSBA titers over time following a primary series and a booster dose of MenB-FHbp.
Cai B; Peyrani P; Beeslaar J; Burman C; Balmer P
Vaccine; 2023 Apr; 41(17):2729-2733. PubMed ID: 37024411
[TBL] [Abstract][Full Text] [Related]
20. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
[No Abstract] [Full Text] [Related]
[Next] [New Search]
